Search Results

You are looking at 221 - 230 of 578 items for :

  • Refine by Access: All x
Clear All
Full access

Safe and Successful Implementation of CPOE for Chemotherapy at a Children's Cancer Center

James M. Hoffman, Donald K. Baker, Scott C. Howard, Joseph H. Laver, and Jerry L. Shenep

, 24 “Alert fatigue,” in which clinicians see several alerts and fail to differentiate those with critically relevant information from the less-informative warnings, is a common problem in the application of CDS. A systematic review of 17 published

Full access

Cancer Rehabilitation: Impact on Breast Cancer Survivors’ Work Ability and Health-Related Quality of Life

Mackenzi Pergolotti, Kelley C. Wood, Tiffany Kendig, Kim Love, and Stacye Mayo

85% 2 ; however, many BCSs report significant challenges in returning to work and experience difficulty maintaining employment. 3 – 5 Upper extremity disability, pain, lymphedema, weakness, fatigue, cognitive problems, and functional limitations are

Full access

Keynote Session: Effects of the Pandemic on Cancer Care/Future Directions of Cancer Care

Presented by: James E. Bachman, Kim Slusser, Thomas K. Varghese, Andrew Wagner, and moderated by Timothy Kubal

consequences. This cannot happen overnight,” Dr. Varghese cautioned. Wellness of Healthcare Workers “With the expected tsunami of late-stage patients, we need to think about the stress and fatigue among our healthcare workers. I’m very concerned, because

Full access

Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Anthony Mato

also well tolerated, according to Dr. Mato, with a 1% rate of treatment discontinuation due to an AE. Common AEs included fatigue, diarrhea, neutropenia, and contusion. Grade 3 or 4 AEs were reported to be rare, and BTK inhibitor–associated events such

Full access

Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies

Presented by: Olalekan O. Oluwole and Salyka Sengsayadeth

90 days in 38%; these side effects put patients at risk for infections, bleeding, and fatigue. CAR T-cell–related cytopenias can be the consequence of lymphodepletion chemotherapy, primary or secondary marrow neoplasms, systemic inflammation, or

Full access

Abstracts From the NCCN 2024 Annual Conference

included 8- and 24-wk TI, hematologic improvement-erythroid (HI-E), duration of TI, and safety. Cytogenetic response (IWG 2006), VAF changes, and patient-reported fatigue were exploratory endpoints. Results: At baseline, median age was 72 y, 67% were IPSS

Full access

Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™

(16%), sleep disturbance (8%), fatigue (5%), cognitive changes (3%), and a general request for help (8%). Clinic staff said the questionnaire was valuable in “taking better care of the patient.” Conclusions: PROMIS GH was well accepted by patients

Full access

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P. Bro, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Mayer Fishman, Thomas H. Gallagher, John L. Gore, Steven L. Hancock, Michael R. Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, M. Dror Michaelson, Thomas Olencki, Phillip M. Pierorazio, Elizabeth R. Plimack, Bruce G. Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, and Rashmi Kumar

significant). Common adverse reactions to pazopanib (any grade) included diarrhea (52%), hypertension (40%), hair color changes, nausea (26%), anorexia (22%), vomiting (21%), fatigue (19%), weakness (14%), abdominal pain (11%), and headache (10%). Notable

Full access

Neoadjuvant Imatinib for Borderline Resectable GIST

M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz

presented to her primary medical doctor complaining of abdominal fullness, early satiety, and fatigue. CBC, comprehensive metabolic panel, thyroid function studies, and C-reactive protein and tissue transglutaminase levels were normal. Her doctor recommended

Full access

Survivorship: Pain Version 1.2014

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass

. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain . J Clin Oncol 2012 ; 30 : 3687 – 3696 . 2. Paice JA Ferrell B . The management of cancer pain . CA Cancer J Clin 2011 ; 61 : 157 – 182 . 3. Raphael